Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b), (c)

On August 5, 2022, the Board of Directors of Haemonetics Corporation (the "Company") appointed James C. D'Arecca, Executive Vice President, Chief Financial Officer, as the Company's principal accounting officer in connection with the previously reported departure of Dan Goldstein, Vice President, Corporate Controller, on or about August 9, 2022. Mr. D'Arecca also serves as the Company's principal financial officer and biographical information with respect to Mr. D'Arecca is incorporated herein from Item 5.02 of the Form 8-K filed by the Company with the SEC on March 21, 2022.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company's 2022 Annual Meeting of Shareholders was held on Friday, August 5, 2022. Of the 51,299,384 shares outstanding and entitled to vote at the meeting, 48,277,405 shares were represented at the meeting, constituting a quorum of 94.1%.

The results of the votes for each proposal considered at the meeting are set forth below:

1. The shareholders elected each of Christopher A. Simon, Robert E. Abernathy, Catherine M. Burzik, Michael J. Coyle, Charles J. Dockendorff, Lloyd E. Johnson, Mark W. Kroll, Claire Pomeroy and Ellen M. Zane as directors for one-year terms expiring in 2023 based upon the following votes:



Nominees                         For           Withhold        Broker Non-Votes
Christopher A. Simon          46,542,318        212,374           1,522,713
Robert E. Abernathy           46,259,954        494,738           1,522,713
Catherine M. Burzik           46,056,687        698,005           1,522,713
Michael J. Coyle              45,582,811       1,171,881          1,522,713
Charles J. Dockendorff        40,796,341       5,958,351          1,522,713
Lloyd E. Johnson              46,073,391        681,301           1,522,713
Mark W. Kroll                 45,970,938        783,754           1,522,713
Claire Pomeroy                46,413,784        340,908           1,522,713
Ellen M. Zane                 43,483,459       3,271,233          1,522,713

2. The shareholders approved, on an advisory basis, the compensation of the Company's named executive officers based upon the following votes:



     For            Against        Abstain        Broker Non-Votes
  43,981,976       2,707,158       65,558            1,522,713

3. The shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending April 1, 2023 based upon the following votes:



     For            Against        Abstain
  47,093,554       1,157,216       26,635

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses